NasdaqGS:IBRXBiotechs
A Look At ImmunityBio (IBRX) Valuation After FDA Review Of ANKTIVA And BCG Combination
FDA review of ANKTIVA combination puts ImmunityBio in focus
ImmunityBio (IBRX) is back on investors’ radar after the US Food and Drug Administration accepted for review a supplemental Biologics License Application for ANKTIVA plus BCG in certain bladder cancer patients.
The filing, supported by additional scientific data, seeks to expand ANKTIVA’s approved use. The company is also outlining potential cost savings for the ANKTIVA and BCG combination compared with other treatment options.
See...